RPC – radient pharmaceuticals (US:NASDAQ)

News

Ridgepost Capital Announces Retirement of Mark Hood as EVP and CAO
Enhanced Capital Named to the ImpactAssets 50 2026, the Definitive Guide to Impact Investing Fund Managers
Ridgepost Capital (RPC) had its price target lowered by Barclays PLC from $12.00 to $11.00. They now have an "overweight" rating on the stock.
P10 (NYSE:RPC) is now covered by analysts at Weiss Ratings. They set a "hold (c)" rating on the stock.
P10 (NYSE:RPC) had its price target lowered by analysts at Barclays PLC from $13.00 to $11.00. They now have an "overweight" rating on the stock.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com